about
Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancerCombination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts.Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.Properties of internalization factors contributing to the uptake of extracellular DNA into tumor-initiating stem cells of mouse Krebs-2 cell line.Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cellsComparative analysis of pathologic processes developing in mice housed in SPF vs non-SPF conditions and treated with cyclophosphamide and dsDNA preparation.Identification of cancer stem cells and a strategy for their elimination.Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas.Nonadherent Spheres With Multiple Myeloma Surface Markers Contain Cells that Contribute to Sphere Formation and Are Capable of Internalizing Extracellular Double-Stranded DNA.Delivery and processing of exogenous double-stranded DNA in mouse CD34+ hematopoietic progenitor cells and their cell cycle changes upon combined treatment with cyclophosphamide and double-stranded DNA.Efficacy of a new cancer treatment strategy based on eradication of tumor-initiating stem cells in a mouse model of Krebs-2 solid adenocarcinoma.Defective Dendritic Cell Cytotoxic Activity of High-Grade Glioma Patients' Results from the Low Expression of Membrane TNFα and Can Be Corrected In Vitro by Treatment with Recombinant IL-2 or Exogenic Double-Stranded DNA.Cancer Stem Cells: Emergent Nature of Tumor EmergencyIdentification of the xenograft and its ascendant sphere-forming cell line as belonging to EBV-induced lymphoma, and characterization of the status of sphere-forming cells"Delayed death" phenomenon: a synergistic action of cyclophosphamide and exogenous DNAEffect of double-stranded DNA on maturation of dendritic cells in vitroUltrastructural analysis of the Krebs-2 ascites cancer cells treated with extracellular double-stranded DNA preparationDouble-Stranded DNA Fragments Bearing Unrepairable Lesions and Their Internalization into Mouse Krebs-2 Carcinoma CellsFeatures of monocyte-derived dendritic cells encompassing a rare subpopulation of cells that are capable of natural internalization of extracellular dsDNA
P50
Q35194151-03FEEF38-3AAD-48CF-99A1-86B63FDA5F00Q35204204-255EC9AE-B4BC-4C04-86D7-E02607007110Q36107301-13B5D994-8C82-46CE-A522-DBCB02F189B9Q36938161-88EAF2AD-6E8A-4CE2-926E-63B6C6558FCBQ39056377-828A4681-F676-4206-92CD-BC8A2F99FFB1Q41040823-F9FEFEC7-FBAA-4210-B021-6738EEDBDEEDQ41832042-7C6ECA98-C161-48CF-972B-375382F0FEB1Q42577697-4452CA31-0203-4EF4-B5B5-9B315309B548Q47836853-A1371182-CA49-4E22-B708-2B9EC3BC5147Q51632567-3EA47851-EA94-4F84-AC34-4639284272F1Q53095961-5F70235E-62DE-48C5-8FFE-6EA15D1E40B0Q55452001-CB72BF8C-0DC4-4ACD-8EED-994804E3B5A5Q55456775-C334111D-4F6B-4580-B900-2B401F6EDB8CQ59798121-23F8B7D6-8A1F-40AC-BF12-ABAD8DFBC1E3Q64065209-2F82314C-6ADB-4499-81FC-207837918852Q64386585-AE89EF1D-4960-4662-81F4-8AA9F13A1AD8Q85071860-A915EA62-F561-4C1D-B3D8-6F92963B43D0Q91538556-7765F117-7AE1-4541-BFB1-27CD4A8C5085Q92717602-4300886A-8AC4-4A91-B461-56E860A34C76Q93116319-45B73FE8-D25C-4B48-8A35-FFC34FBEA2C6
P50
description
investigador
@es
researcher
@en
name
Evgenia V Dolgova
@en
type
label
Evgenia V Dolgova
@en
prefLabel
Evgenia V Dolgova
@en
P31
P496
0000-0002-5543-248X